Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS
Tatjana Sajic,
Yansheng Liu,
Eirini Arvaniti,
Silvia Surinova,
Evan G. Williams,
Ralph Schiess,
Ruth Hüttenhain,
Atul Sethi,
Sheng Pan,
Teresa A. Brentnall,
Ru Chen,
Peter Blattmann,
Betty Friedrich,
Emma Niméus,
Susanne Malander,
Aurelius Omlin,
Silke Gillessen,
Manfred Claassen,
Ruedi Aebersold
Affiliations
Tatjana Sajic
Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland
Yansheng Liu
Department of Pharmacology, Cancer Biology Institute, Yale University School of Medicine, West Haven, CT 06516, USA
Eirini Arvaniti
Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland
Silvia Surinova
UCL Cancer Institute, University College London, London, UK
Evan G. Williams
Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland
Ralph Schiess
ProteoMediX AG, 8952 Schlieren, Switzerland
Ruth Hüttenhain
Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA
Atul Sethi
Department of Biomedicine, University of Basel/University Hospital Basel, and Swiss Institute of Bioinformatics, Basel, Switzerland
Sheng Pan
The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1825 Pressler, Houston, TX 77030, USA
Teresa A. Brentnall
Department of Medicine, University of Washington, Seattle, WA 98195, USA
Ru Chen
Department of Medicine, University of Washington, Seattle, WA 98195, USA
Peter Blattmann
Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland
Betty Friedrich
Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland
Emma Niméus
Department of Clinical Sciences Lund, Surgery, Oncology and Pathology, Lund University, and Skåne University Hospital, Department of Surgery, Lund, Sweden
Susanne Malander
Department of Clinical Sciences Lund, Oncology and Pathology, Lund University, and Skåne University Hospital, Department of Oncology, Lund, Sweden
Aurelius Omlin
Department of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Silke Gillessen
Department of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Manfred Claassen
Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland
Ruedi Aebersold
Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland
Cancer is mostly incurable when diagnosed at a metastatic stage, making its early detection via blood proteins of immense clinical interest. Proteomic changes in tumor tissue may lead to changes detectable in the protein composition of circulating blood plasma. Using a proteomic workflow combining N-glycosite enrichment and SWATH mass spectrometry, we generate a data resource of 284 blood samples derived from patients with different types of localized-stage carcinomas and from matched controls. We observe whether the changes in the patient’s plasma are specific to a particular carcinoma or represent a generic signature of proteins modified uniformly in a common, systemic response to many cancers. A quantitative comparison of the resulting N-glycosite profiles discovers that proteins related to blood platelets are common to several cancers (e.g., THBS1), whereas others are highly cancer-type specific. Available proteomics data, including a SWATH library to study N-glycoproteins, will facilitate follow-up biomarker research into early cancer detection.
